Moderna Merck mRNA Cancer Vaccine Results: 50 Percent Risk Reduction
Moderna and Merck's mRNA cancer vaccine combined with Keytruda reduced melanoma recurrence risk by 50% in a 5-year study. Read the latest Phase 2 trial insights.
The fight against cancer just took a massive leap forward. Moderna and Merck recently shared updated data from a small clinical trial showing their customized mRNA cancer vaccine reduced the risk of recurrence or death by nearly 50% over 5 years. It's a significant milestone for the experimental therapy known as mRNA-4157 (V940).
Analyzing the Moderna Merck mRNA Cancer Vaccine Results
The Phase 2 trial focused on 157 patients with Stage 3 or Stage 4 melanoma. These individuals faced a high risk of the cancer returning even after surgical removal. According to the companies, the latest results align with earlier data collected at the two-year and three-year marks, suggesting the vaccine's benefits are durable over the long term.
How mRNA-4157 Works with Keytruda
The treatment combines the customized vaccine with Merck's immunotherapy drug, Keytruda. While Keytruda unmasks cancer cells so the immune system can attack them, the mRNA vaccine goes a step further. It's tailored to the specific genetic mutations of a patient's tumor, essentially training T-cells to recognize and destroy those unique targets. This dual-action approach is what makes the results so promising.
Authors
Related Articles
FDA refuses to review Moderna's mRNA flu vaccine application, marking a shift in vaccine policy under RFK Jr's leadership
Waymo's new Ojai robotaxi isn't just a vehicle upgrade. It's the company's most serious attempt yet at cracking the cost problem that has kept autonomous vehicles from scaling. Here's what's really at stake.
Snowflake's new $6 billion AWS contract is about more than cloud spending. It signals a shift in AI infrastructure—away from Nvidia GPUs and toward cheaper, homegrown chips for the agent era.
China is restricting AI researchers and startup founders from traveling abroad as the U.S.-China AI performance gap narrows to just 2.7%. What Beijing's talent lockdown means for the global AI race.
FDA refuses to review Moderna's mRNA flu vaccine application, marking a shift in vaccine policy under RFK Jr's leadership
Waymo's new Ojai robotaxi isn't just a vehicle upgrade. It's the company's most serious attempt yet at cracking the cost problem that has kept autonomous vehicles from scaling. Here's what's really at stake.
Snowflake's new $6 billion AWS contract is about more than cloud spending. It signals a shift in AI infrastructure—away from Nvidia GPUs and toward cheaper, homegrown chips for the agent era.
China is restricting AI researchers and startup founders from traveling abroad as the U.S.-China AI performance gap narrows to just 2.7%. What Beijing's talent lockdown means for the global AI race.
Thoughts
Share your thoughts on this article
Sign in to join the conversation